Environmental Toxins and Alzheimer’s Disease: a Comprehensive Analysis of Pathogenic Mechanisms and Therapeutic Modulation

被引:0
|
作者
Rishika Dhapola
Prajjwal Sharma
Sneha Kumari
Jasvinder Singh Bhatti
Dibbanti HariKrishnaReddy
机构
[1] Central University of Punjab,Advanced Pharmacology and Neuroscience Laboratory, Department of Pharmacology
[2] Central University of Punjab,Laboratory of Translational Medicine and Nanotherapeutics, Department of Human Genetics and Molecular Medicine
来源
Molecular Neurobiology | 2024年 / 61卷
关键词
Alzheimer’s disease; Environmental pollutants; Heavy metals; PARP; SIRT1; MAPK/ERK;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease is a leading cause of mortality worldwide. Inorganic and organic hazards, susceptibility to harmful metals, pesticides, agrochemicals, and air pollution are major environmental concerns. As merely 5% of AD cases are directly inherited indicating that these environmental factors play a major role in disease development. Long-term exposure to environmental toxins is believed to progress neuropathology, which leads to the development of AD. Numerous in-vitro and in-vivo studies have suggested the harmful impact of environmental toxins at cellular and molecular level. Common mechanisms involved in the toxicity of these environmental pollutants include oxidative stress, neuroinflammation, mitochondrial dysfunction, abnormal tau, and APP processing. Increased expression of GSK-3β, BACE-1, TNF-α, and pro-apoptotic molecules like caspases is observed upon exposure to these environmental toxins. In addition, the expression of neurotrophins like BDNF and GAP-43 have been found to be reduced as a result of toxicity. Further, modulation of signaling pathways involving PARP-1, PGC-1α, and MAPK/ERK induced by toxins have been reported to contribute in AD pathogenesis. These pathways are a promising target for developing novel AD therapeutics. Drugs like epigallocatechin-gallate, neflamapimod, salsalate, dexmedetomidine, and atabecestat are in different phases of clinical trials targeting the pathways for possible treatment of AD. This review aims to culminate the correlation between environmental toxicants and AD development. We emphasized upon the signaling pathways involved in the progression of the disease and the therapeutics under clinical trial targeting the altered pathways for possible treatment of AD.
引用
收藏
页码:3657 / 3677
页数:20
相关论文
共 50 条
  • [31] cGMP modulation as a novel therapeutic target for Alzheimer's disease
    Seker, Burcu
    Sandner, Peter
    Sienel, Rebecca
    Dorok, Maximilian
    Plesnila, Nikolaus
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (SUPPL 1)
  • [32] cGMP modulation as a novel therapeutic target for Alzheimer's disease
    Seker, Burcu
    Sandner, Peter
    Sienel, Rebecca
    Dorok, Maximilian
    Plesnila, Nikolaus
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21
  • [33] MicroRNAs modulation: a new therapeutic approach for Alzheimer's disease
    Viegas, A.
    Carmona, V.
    Guedes, J.
    Oliveira, A. R.
    Pereira de Almeida, L.
    Resende de Oliveira, C.
    De Magalhaes, J. P.
    Cardoso, A. L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S635 - S636
  • [34] Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer's disease
    Isaac G.Onyango
    Neural Regeneration Research, 2018, 13 (01) : 19 - 25
  • [35] Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer's disease
    Onyango, Isaac G.
    NEURAL REGENERATION RESEARCH, 2018, 13 (01) : 19 - 25
  • [36] Pathogenic mechanisms of heavy metal induced-Alzheimer’s disease
    Lee H.J.
    Park M.K.
    Seo Y.R.
    Toxicology and Environmental Health Sciences, 2018, 10 (1) : 1 - 10
  • [37] Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications
    El Khoury, Joseph
    Luster, Andrew D.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (12) : 626 - 632
  • [38] Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications
    Altuna, Miren
    Olmedo-Saura, Gonzalo
    Carmona-Iragui, Maria
    Fortea, Juan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (08)
  • [39] Galanin: Neurobiologic mechanisms and therapeutic potential for Alzheimer's disease
    Counts, SE
    Perez, SE
    Kahl, U
    Bartfai, T
    Bowser, RP
    Deecher, DC
    Mash, DC
    Crawley, JN
    Mufson, EJ
    CNS DRUG REVIEWS, 2001, 7 (04): : 445 - 470
  • [40] Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms
    Halliday, G
    Robinson, SR
    Shepherd, C
    Kril, J
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2000, 27 (1-2) : 1 - 8